Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Molecular Partners AG ADR (MOLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.71
1 Year Target Price $10.71
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.94% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 135.15M USD | Price to earnings Ratio - | 1Y Target Price 10.71 |
Price to earnings Ratio - | 1Y Target Price 10.71 | ||
Volume (30-day avg) 4 | Beta 0.55 | 52 Weeks Range 3.36 - 7.60 | Updated Date 08/10/2025 |
52 Weeks Range 3.36 - 7.60 | Updated Date 08/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2755.42% |
Management Effectiveness
Return on Assets (TTM) -23.53% | Return on Equity (TTM) -40.1% |
Valuation
Trailing PE - | Forward PE 1.78 | Enterprise Value -25258617 | Price to Sales(TTM) 60.55 |
Enterprise Value -25258617 | Price to Sales(TTM) 60.55 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 36874600 | Shares Floating 11386426 |
Shares Outstanding 36874600 | Shares Floating 11386426 | ||
Percent Insiders - | Percent Institutions 9.72 |
Upturn AI SWOT
Molecular Partners AG ADR
Company Overview
History and Background
Molecular Partners AG, founded in 2004 in Zurich, Switzerland, is a clinical-stage biopharmaceutical company focused on developing a new class of custom-built protein therapeutics known as DARPins. It has evolved from a research-driven startup to a company with a pipeline of clinical and preclinical programs.
Core Business Areas
- DARPin Therapeutics: Development and commercialization of DARPin therapeutics for various diseases, including ophthalmology and oncology.
- Strategic Partnerships: Collaborations with pharmaceutical companies to develop and commercialize DARPin-based therapeutics.
Leadership and Structure
The company is led by a management team with experience in biopharmaceutical development and commercialization. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Abicipar (Partnered with AbbVie): A DARPin therapeutic for neovascular age-related macular degeneration (nAMD). While AbbVie discontinued development, the clinical data generated provides value to Molecular Partners. Competitors include Regeneron (Eylea) and Roche/Novartis (Lucentis/Beovu). Market share data is unavailable as it was not commercialized.
- Ensovibep (Partnered with Novartis): A DARPin therapeutic for COVID-19. Competitors include antivirals from Pfizer (Paxlovid) and Merck (Molnupiravir) and antibody treatments. Ensovibep market share data is not available due to the changing nature of the pandemic response and its authorization status across regions.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. There's increasing demand for novel therapeutics with improved efficacy and safety profiles.
Positioning
Molecular Partners AG ADR is positioned as an innovator in the field of protein therapeutics, leveraging its DARPin technology platform to develop differentiated therapies. Its competitive advantage lies in the unique properties of DARPins, such as high binding affinity and modular design.
Total Addressable Market (TAM)
The TAM varies depending on the specific therapeutic area. The overall global market for biopharmaceuticals is in the hundreds of billions of dollars, and the company targets specific segments within that. Molecular Partners AG ADR is positioned to capture a share of this market with its innovative DARPin therapeutics.
Upturn SWOT Analysis
Strengths
- Novel DARPin technology platform
- Strategic partnerships with major pharmaceutical companies
- Pipeline of clinical and preclinical programs
- Experienced management team
Weaknesses
- Reliance on partnerships for commercialization
- High R&D costs and regulatory hurdles
- Limited independent commercial infrastructure
- Clinical trial risks
Opportunities
- Expanding DARPin technology to new therapeutic areas
- Developing proprietary DARPin therapeutics
- Securing regulatory approvals for key products
- Expanding partnerships to new markets
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Economic downturns
Competitors and Market Share
Key Competitors
- RGNX
- VRTX
- AMGN
Competitive Landscape
Molecular Partners AG ADR competes with established pharmaceutical companies and other biotechnology firms in the development of novel therapeutics. Its DARPin technology offers a unique competitive advantage, but it faces challenges in commercialization and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its DARPin technology and the establishment of strategic partnerships.
Future Projections: Future growth is contingent on the successful development and commercialization of its DARPin therapeutics. Analyst estimates vary widely depending on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Focus on advancing its clinical pipeline, expanding its DARPin technology platform, and securing new partnerships.
Summary
Molecular Partners AG ADR is a biopharmaceutical company with a novel DARPin technology platform. Its success relies heavily on clinical trial outcomes and strategic partnerships. The company's financial performance is volatile, and it faces competition from larger pharmaceutical companies. Future growth depends on successful pipeline development and commercialization efforts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Molecular Partners AG ADR Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is subject to change without notice. Market share estimates are approximate and may not reflect the most current data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | |
Full time employees 158 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.